PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
2024 G. Castaman, F. Peyvandi, J.A. Kremer Hovinga, R.E.G. Schutgens, S. Robson, K. Moreno, V. Jiménez-Yuste
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
2024 G. Di Minno, W. Miesbach, G. Castaman, F. Peyvandi
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
2024 R. Lemons, M. Wang, J. Curtin, L.M. Lepatan, C. Male, F. Peyvandi, M. von Depka Prondzinski, R. Wang, W. Mckeand, W. Seifert, J. Oldenburg
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results
2024 C. Hermans, L.A. Valentino, C.D. Thornburg, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, W. Mckeown, G.F. Pierce, K. Khair, S.W. Pipe, K. Starcevic, M. Pillai, M. Jones, M. Chiao, I. Antonino, C. Kessler
Comprehensive investigation of platelet function in patients with cirrhosis
2024 A. Lecchi, G. Tosetti, C. Ghali, S. La Marca, M. Clerici, L. Padovan, E.A. Femia, M. Primignani, V. La Mura, P. Lampertico, F. Peyvandi, A. Tripodi
Gene therapy for people with Haemophilia B: a proposed care delivery model in Italy
2024 G. Castaman, G. Di Minno, P. Simioni, A.C. Molinari, S. Siragusa, E. Baldacci, V. La Mura, A. Lupi, E.F. Grazzi, F. Peyvandi
Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19
2024 R. Rossio, M. Tettamanti, A.A. Galbussera, R. Gualtierotti, A. Giachi, A. Torri, N. Montano, A.L. Fracanzani, A. Bandera, A. Nobili, F. Peyvandi
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
2024 S.W. Pipe, P. Collins, C. Dhalluin, G. Kenet, C. Schmitt, M. Buri, V. Jiménez-Yuste, F. Peyvandi, G. Young, J. Oldenburg, M.E. Mancuso, K. Kavakli, A. Kiialainen, S. Deb, M. Niggli, T. Chang, M. Lehle, K. Fijnvandraat
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy
2024 A. Lombardi, S. Villa, M. Colaneri, G. Scaglione, F. Bai, B. Varisco, V. Bono, A. Vena, C. Dentone, C. Russo, M. Tettamanti, G. Renisi, G. Viero, C. Azzarà, M. Mantero, F. Peyvandi, M. Bassetti, G. Marchetti, A. Muscatello, A. Nobili, A. Gori, A. Bandera, S. Bosari, L. Scudeller, G. Fusetti, L. Rusconi, S. Dell’Orto, D. Prati, L. Valenti, S. Giovannelli, M. Manunta, G. Lamorte, F. Ferarri, D. Mangioni, L. Alagna, G. Bozzi, A. Lombardi., R. Ungaro, G. Ancona, M. Mussa, B.V. Mariani, M. Bolis, N. Iannotti, S. Ludovisi, A. Comelli, S. Biscarini, V. Castelli, E. Palomba, M. Fava, C.A. Peri, P. Saltini, T. Itri, V. Ferroni, V. Pastore, R. Massafra, A. Liparoti, T. Muheberimana, A. Giommi, R. Bianco, G.E. Chitani, C. Bobbio, I. De Matteis, A.B. Bonomi, R. Gualtierotti, B. Ferrari, R. Rossio, N. Boasi, E. Pagliaro, C. Massimo, M. De Caro, A. Giachi, N. Montano, B. Vigone, C. Bellocchi, A. Carandina, E. Fiorelli, V. Melli, E. Tobaldini, F. Blasi, S. Aliberti, M. Spotti, L. Terranova, S. Misuraca, A. D’Adda, S. Della Fiore, M. Di Pasquale, M. Contarini, M. Ori, L. Morlacchi, V. Rossetti, A. Gramegna, M. Pappalettera, M. Cavallini, A. Buscemi, M. Vicenzi, I. Rota, G. Costantino, M. Solbiati, L. Furlan, M. Mancarella, G. Colombo, G. Colombo, A. Fanin, M. Passarella, V. Monzani, C. Canetta, A. Rovellini, L. Barbetta, F. Billi, C. Folli, S. Accordino, D. Maira, C.M. Hu, I. Motta, N. Scaramellini, A.L. Fracanzani, R. Lombardi, A. Cespiati, M. Cesari, T. Lucchi, M. Proietti, L. Calcaterra, C. Mandelli, C. Coppola, A. Cerizza, A.M. Pesenti, G. Grasselli, A. Galazzi, I. Monti, A.A. Galbussera, E. Crisafulli, D. Girelli, A. Maroccia, D. Gabbiani, F. Busti, A. Vianello, M. Biondan, F. Sartori, P. Faverio, A. Pesci, S. Zucchetti, P. Bonfanti, M. Rossi, I. Beretta, A. Spolti, S. Harari, D. Elia, R. Cassandro, A. Caminati, F. Cipollone, M.T. Guagnano, D. D’Ardes, I. Rossi, F. Vezzani, A. Spanevello, F. Cherubino, D. Visca, M. Contoli, A. Papi, L. Morandi, N. Battistini, G.L. Moreo, P. Iannuzzi, D. Fumagalla, S. Leone
IgM autoantibodies to complement factor H in C3 glomerulopathy
2024 M. Cugno, M.C. Mancuso, F. Depetri, F. Peyvandi, G. Ardissino
Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
2024 J.A. Giannotta, A. Artoni, I. Mancini, P. Agosti, M. Carpenedo, A. Truma, S. Miri, B. Ferrari, P. De Leo, P. Salutari, G. Mancini, A. Molteni, E. Rinaldi, M. Bocchia, M. Napolitano, L. Prezioso, A. Cuccaro, E. Scarpa, A. Condorelli, D. Grimaldi, M. Massaia, F. Peyvandi
Assessing joint health in haemophilia patients: The combined value of physical examination and ultrasound imaging
2024 R. Gualtierotti, A. Giachi, A. Truma, S. Arcudi, A. Ciavarella, P. Bucciarelli, D. Consonni, E. Boccalandro, V. Begnozzi, L.P. Solimeno, S.M. Siboni, F. Peyvandi
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation
2024 A. Tripodi, M. Capecchi, E. Scalambrino, M. Clerici, B. Scimeca, P. Agosti, P. Bucciarelli, F. Peyvandi
Insights on the Development of PRACTICE, A Research-Oriented Healthcare Platform
2024 D. Ahmetovic, A. Angileri, S. Arcudi, C. Bettini, G. Civitarese, M. Colussi, A. Giachi, R. Gualtierotti, S. Mascetti, M. Manzoni, F. Peyvandi, A. Solyman, A. Truma
Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
2024 S. Agarwal, C. Hermans, W. Miesbach, F. Peyvandi, R. Sidonio, D. Osmond, V. Newman, J. Henshaw, S. Pipe
Rare inherited coagulation disorders: no longer orphan and neglected
2024 S. Mohsenian, P.M. Mannucci, M. Menegatti, F. Peyvandi
Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List
2024 G.F. Pierce, B. O'Mahony, R. Kaczmarek, M.W. Skinner, M. Makris, F. Peyvandi, A. Srivastava, C. Hermans, M. Crato, A. Dunn, E. Gouider, J. Mahlangu, D. Page, S.W. Pipe, M. Recht, T. Sannie, N. Schaefer, U. Schlenkrich, C. Garrido
Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A
2024 O. Seidizadeh, L. Mollica, S. Zambarbieri, L. Baronciani, A. Cairo, P. Colpani, G. Cozzi, M.T. Pagliari, A. Ciavarella, S.M. Siboni, F. Peyvandi
Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life
2024 M. Morfini, F. Peyvandi, M.E. Mancuso, E. Marchesini, A. Tagliaferri, R. Gualtierotti, G. Castaman, B. Pollio, C. Santoro, L. Banov, M. Napolitano, P.S. Preti, R.C. Santoro, A. Coppola, S. Linari, E. Santagostino, F. Bernardi
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura
2024 K. Pavenski, M. Scully, P. Coppo, S. Cataland, P. Knöbl, F. Peyvandi, J.A. Kremer Hovinga, J. de la Rubia, U. Khan, A.P. Marques, S. Gunawardena